Additionally, the drug has been shown to facilitate proliferation and migration of breast cancer cells, suggesting potential crosstalk between cardiovascular therapeutics and oncogenic pathways, while raising concerns about unintended consequences in individuals with both CHIP and obesity [110]. The gene discussed is STUB1; the disease is obesity due to melanocortin 4 receptor deficiency.